[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-001", "question": "A 16-year-old female presents with episodes of muscle weakness and palpitations. Physical exam reveals low-set ears, micrognathia, and clinodactyly. ECG demonstrates frequent PVCs, a QTc of 490 ms, and prominent U waves. Genetic testing confirms a loss-of-function mutation in KCNJ2. She continues to have frequent non-sustained ventricular tachycardia despite beta-blocker therapy. What is the most appropriate pharmacologic management for her arrhythmia?", "options": ["Option A: Nadolol", "Option B: Amiodarone", "Option C: Flecainide", "Option D: Mexiletine", "Option E: Verapamil"], "answer": "C", "answer_index": 2, "explanation": "This patient has Andersen-Tawil Syndrome (LQT7), characterized by the triad of periodic paralysis, dysmorphic features, and QT/U wave abnormalities. Unlike other Long QT Syndromes where sodium channel blockers are often contraindicated, Flecainide is uniquely effective in suppressing the ventricular arrhythmias associated with KCNJ2 mutations.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nThe patient has:\n- Episodic muscle weakness\n- Palpitations\n- Dysmorphic features (low-set ears, micrognathia, clinodactyly)\n- ECG: frequent PVCs, prolonged QTc (490 ms), prominent U waves\n- KCNJ2 loss-of-function mutation\n- Refractory to beta-blocker therapy\n\nThis presentation is classic for Andersen-Tawil Syndrome (ATS) or Long QT Syndrome Type 7 (LQT7). KCNJ2 encodes the Kir2.1 potassium channel responsible for the inward rectifier current (IK1). The triad includes:\n1. Periodic paralysis (muscle weakness)\n2. Cardiac arrhythmias (prolonged QT, prominent U waves, bidirectional VT)\n3. Dysmorphic features\n\nFor Andersen-Tawil Syndrome with arrhythmias refractory to beta-blockers:\n\n- Nadolol (Option A): She's already on beta-blocker therapy without adequate response\n- Amiodarone (Option B): Generally avoided due to QT prolongation and other toxicities\n- Flecainide (Option C): Has been used successfully in ATS, particularly for bidirectional VT and frequent PVCs, as it can suppress the arrhythmias. It's considered a reasonable option in ATS specifically.\n- Mexiletine (Option D): A sodium channel blocker that can shorten QT interval and is used in LQT3, but less evidence in ATS\n- Verapamil (Option E): Has some evidence in ATS for suppressing arrhythmias\n\nIn Andersen-Tawil Syndrome specifically, flecainide has emerged as an effective treatment option for ventricular arrhythmias that are refractory to beta-blockers. Multiple case reports and small series have shown flecainide to be effective in suppressing the characteristic bidirectional VT and frequent PVCs seen in this condition.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-002", "question": "A 55-year-old man presents with bone pain and exophthalmos. CT imaging reveals perinephric infiltration with a 'hairy kidney' appearance and osteosclerotic lesions in the distal femur. Biopsy of the retroperitoneal tissue shows infiltration by foamy histiocytes that are CD68+ and CD1a-. Molecular testing reveals a BRAF V600E mutation. Which therapeutic agent is most indicated?", "options": ["Option A: Rituximab", "Option B: High-dose Prednisone", "Option C: Vemurafenib", "Option D: Methotrexate", "Option E: Infliximab"], "answer": "C", "answer_index": 2, "explanation": "The clinical presentation (hairy kidney, osteosclerosis, exophthalmos) and pathology (CD68+, CD1a- foamy histiocytes) are diagnostic of Erdheim-Chester Disease (ECD), a non-Langerhans cell histiocytosis. Over 50% of cases carry the BRAF V600E mutation. Targeted therapy with a BRAF inhibitor (Vemurafenib) is the treatment of choice for BRAF-positive ECD, superior to empiric immunosuppression.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nClinical Presentation:\n- 55-year-old man with bone pain and exophthalmos\n- CT showing perinephric infiltration with 'hairy kidney' appearance\n- Osteosclerotic lesions in distal femur\n\nPathology:\n- Foamy histiocytes\n- CD68+ (histiocyte marker - positive)\n- CD1a- (negative, which rules out Langerhans cell histiocytosis)\n\nMolecular Finding:\n- BRAF V600E mutation\n\nDiagnosis:\nThis presentation is classic for Erdheim-Chester Disease (ECD):\n- Non-Langerhans cell histiocytosis\n- Characteristic \"hairy kidney\" appearance from perinephric infiltration\n- Osteosclerotic (not lytic) bone lesions, typically in long bones\n- Exophthalmos from orbital involvement\n- CD68+, CD1a- foamy histiocytes\n- BRAF V600E mutation present in approximately 50-60% of cases\n\nTreatment Considerations:\n\n- Rituximab (A): Anti-CD20, used for B-cell malignancies - not indicated here\n- High-dose Prednisone (B): Traditional treatment but limited efficacy\n- Vemurafenib (C): BRAF V600E inhibitor - FDA approved for ECD with BRAF mutation\n- Methotrexate (D): Not standard treatment for ECD\n- Infliximab (E): TNF-alpha inhibitor, sometimes used but not first-line for BRAF-mutated disease\n\nBest Answer:\nGiven the presence of BRAF V600E mutation, Vemurafenib is the most indicated therapy. It was FDA-approved for Erdheim-Chester Disease with BRAF V600E mutation in 2017, representing a targeted therapy approach with high response rates in this specific molecular subset.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-003", "question": "A 32-year-old G1P0 woman at 35 weeks gestation presents with nausea, vomiting, and jaundice. Labs show AST 300 U/L, ALT 350 U/L, Platelets 80,000/mm3, Glucose 45 mg/dL, and INR 2.5. A diagnosis of Acute Fatty Liver of Pregnancy (AFLP) is made, and the infant is delivered urgently. To prevent sudden death in the neonate, which specific screening test should be prioritized?", "options": ["Option A: Serum ammonia and lactate", "Option B: Plasma acylcarnitine profile", "Option C: Galactose-1-phosphate uridyltransferase", "Option D: Very long-chain fatty acids (VLCFA)", "Option E: Hemoglobin electrophoresis"], "answer": "B", "answer_index": 1, "explanation": "Maternal AFLP is strongly associated with fetal Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. Fetal fatty acid oxidation defects cause accumulation of metabolites that cross the placenta and overwhelm the maternal liver. The neonate is at high risk for hypoketotic hypoglycemia and sudden death; an acylcarnitine profile is diagnostic.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case of Acute Fatty Liver of Pregnancy (AFLP) and determine the appropriate neonatal screening.\n\nAFLP is strongly associated with fetal defects in fatty acid oxidation, particularly Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase (LCHAD) deficiency. When the fetus has LCHAD deficiency, it cannot properly metabolize long-chain fatty acids. These abnormal metabolites accumulate and cross the placenta, causing hepatotoxicity in the mother.\n\nThe key associations:\n- AFLP and HELLP syndrome can occur when the fetus is homozygous for LCHAD deficiency\n- The mother is typically a heterozygous carrier\n- Neonates with LCHAD deficiency are at risk for sudden death from:\n  - Hypoketotic hypoglycemia\n  - Cardiomyopathy\n  - Hepatic failure\n\nLet me evaluate each option:\n\nA. Serum ammonia and lactate - These are general metabolic markers but not specific for fatty acid oxidation defects\n\nB. Plasma acylcarnitine profile - This is the specific test to detect fatty acid oxidation disorders including LCHAD deficiency. It would show elevated long-chain hydroxyacylcarnitines (particularly C16-OH and C18:1-OH)\n\nC. Galactose-1-phosphate uridyltransferase - This tests for galactosemia, unrelated to AFLP\n\nD. Very long-chain fatty acids (VLCFA) - This tests for peroxisomal disorders like adrenoleukodystrophy, not mitochondrial fatty acid oxidation defects\n\nE. Hemoglobin electrophoresis - Tests for hemoglobinopathies, unrelated to AFLP\n\nThe plasma acylcarnitine profile is the gold standard screening test for fatty acid oxidation disorders, including LCHAD deficiency, which is the condition most strongly associated with AFLP and poses the greatest risk of sudden death in the neonate.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-004", "question": "A 24-year-old male with HIV and known G6PD deficiency develops cyanosis and dyspnea after receiving dapsone. SpO2 is 85% and arterial blood is chocolate-colored. Methemoglobin level is 25%. He is inadvertently treated with methylene blue, after which his condition deteriorates with evidence of acute hemolysis and worsening hypoxia. What is the most appropriate next step in management?", "options": ["Option A: Repeat Methylene Blue dose", "Option B: High-dose Ascorbic Acid (Vitamin C)", "Option C: Exchange transfusion", "Option D: Hyperbaric oxygen therapy", "Option E: Hydroxocobalamin"], "answer": "C", "answer_index": 2, "explanation": "Methylene blue requires NADPH (generated via the G6PD pathway) to reduce methemoglobin. In G6PD deficiency, it is ineffective and can induce severe hemolysis (as seen here). Ascorbic acid is too slow for acute severe toxicity. Exchange transfusion is the definitive rescue therapy to rapidly remove the methemoglobin and the offending agent.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nClinical Scenario:\n- 24-year-old male with HIV and G6PD deficiency\n- Developed cyanosis and dyspnea after dapsone (a known oxidizing agent)\n- SpO2 85%, chocolate-colored blood\n- Methemoglobin level 25%\n- Given methylene blue â†’ condition worsened with acute hemolysis and worsening hypoxia\n\nKey Issues:\n\n1. Methemoglobinemia from dapsone: Dapsone is an oxidizing agent that can cause methemoglobinemia. The chocolate-colored blood and elevated methemoglobin level (25%) confirm this diagnosis.\n\n2. G6PD deficiency complication: Methylene blue is the standard treatment for methemoglobinemia, BUT it requires NADPH (generated by the G6PD-dependent hexose monophosphate shunt) to work. In G6PD deficiency:\n   - Methylene blue cannot be reduced to leukomethylene blue (the active form)\n   - Methylene blue itself becomes an oxidizing agent\n   - This causes hemolysis and paradoxically worsens methemoglobinemia\n\n3. Current situation: The patient now has both severe methemoglobinemia AND acute hemolysis from the methylene blue.\n\nEvaluating Options:\n\nA. Repeat Methylene Blue - Contraindicated; it caused the hemolysis and won't work in G6PD deficiency\n\nB. High-dose Ascorbic Acid - Can reduce methemoglobin but works very slowly; not adequate for severe/acute cases\n\nC. Exchange transfusion - Removes both methemoglobin and the offending drug, replaces with functional RBCs; definitive treatment when methylene blue is contraindicated\n\nD. Hyperbaric oxygen - Can help with oxygen delivery but doesn't address the underlying methemoglobinemia or hemolysis directly\n\nE. Hydroxocobalamin - Used for cyanide poisoning, not methemoglobinemia\n\nBest Answer:\nIn G6PD-deficient patients with severe methemoglobinemia where methylene blue is contraindicated or has failed, exchange transfusion is the treatment of choice. It removes the dysfunctional hemoglobin and provides normal RBCs capable of oxygen transport.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-005", "question": "A 3-month-old male presents with generalized erythroderma, lymphadenopathy, hepatosplenomegaly, and chronic diarrhea. CBC reveals eosinophilia and lymphocytosis. Immunophenotyping shows an absence of B cells, but elevated numbers of oligoclonal, activated T cells. Which genetic defect is most consistent with this presentation?", "options": ["Option A: BTK mutation", "Option B: Hypomorphic RAG1/RAG2 mutation", "Option C: CD40 Ligand mutation", "Option D: STAT3 mutation", "Option E: WAS gene mutation"], "answer": "B", "answer_index": 1, "explanation": "This is Omenn Syndrome, a form of 'leaky' Severe Combined Immunodeficiency (SCID). It is caused by hypomorphic mutations in RAG1 or RAG2 that allow for partial V(D)J recombination. This results in the absence of B cells but the development of a restricted, autoreactive T-cell repertoire that infiltrates tissues (erythroderma, hepatosplenomegaly) and causes high IgE/eosinophilia.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nClinical Presentation:\n- 3-month-old male\n- Generalized erythroderma\n- Lymphadenopathy\n- Hepatosplenomegaly\n- Chronic diarrhea\n- Eosinophilia and lymphocytosis\n- Absence of B cells\n- Elevated oligoclonal, activated T cells\n\nKey Features to Consider:\nThe combination of erythroderma, lymphadenopathy, hepatosplenomegaly, diarrhea, eosinophilia, absent B cells, and oligoclonal T cells is classic for Omenn Syndrome.\n\nAnalyzing Options:\n\nA. BTK mutation - X-linked agammaglobulinemia. Would have absent B cells but also very low T cells wouldn't be elevated. No erythroderma or eosinophilia typically.\n\nB. Hypomorphic RAG1/RAG2 mutation - This causes Omenn Syndrome. RAG genes are essential for V(D)J recombination. Complete loss = SCID with no T or B cells. Hypomorphic (partial function) mutations allow some T cell development but with restricted repertoire (oligoclonal), leading to autoreactive, activated T cells that infiltrate skin and gut, causing erythroderma and diarrhea. B cells are absent. Eosinophilia is characteristic.\n\nC. CD40 Ligand mutation - Hyper-IgM syndrome. Would have normal T cells, elevated IgM, low IgG/IgA. Doesn't fit this presentation.\n\nD. STAT3 mutation - Hyper-IgE syndrome (Job syndrome). Would have elevated IgE, recurrent skin/lung infections, but not this specific immunophenotype.\n\nE. WAS gene mutation - Wiskott-Aldrich syndrome. Classic triad: eczema, thrombocytopenia, immunodeficiency. Would have small platelets, not this specific T/B cell pattern.\n\nConclusion:\nThe presentation is classic for Omenn Syndrome, caused by hypomorphic RAG1/RAG2 mutations. The partial RAG function allows development of a limited T cell repertoire (oligoclonal) that becomes activated and autoreactive, while B cell development is blocked.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-006", "question": "A 4-month-old infant presents with failure to thrive and diaphoresis during feeding. ECG reveals deep Q waves in leads I, aVL, and V5-V6. Echocardiography demonstrates a dilated left ventricle. During color Doppler interrogation of the coronary arteries, which flow pattern confirms the diagnosis of Anomalous Left Coronary Artery from the Pulmonary Artery (ALCAPA)?", "options": ["Option A: Diastolic flow from the aorta into the left coronary artery", "Option B: Systolic flow from the pulmonary artery into the left coronary artery", "Option C: Retrograde flow from the left coronary artery into the pulmonary artery", "Option D: Continuous flow from the aorta to the pulmonary artery", "Option E: Turbulent high-velocity flow at the left coronary ostium"], "answer": "C", "answer_index": 2, "explanation": "In the infant/adult type of ALCAPA, pulmonary vascular resistance drops, causing flow reversal. Blood flows from the aorta to the Right Coronary Artery, through collaterals to the Left Coronary Artery, and then retrograde into the low-pressure Pulmonary Artery (coronary steal). The hallmark is retrograde flow into the PA.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me work through this question about ALCAPA (Anomalous Left Coronary Artery from the Pulmonary Artery).\n\nIn ALCAPA, the left coronary artery originates from the pulmonary artery instead of the aorta. Here's the pathophysiology:\n\n1. In fetal life, pulmonary artery pressure is high, so the anomalous left coronary receives adequate perfusion\n2. After birth, pulmonary artery pressure drops significantly\n3. The left coronary now receives poorly oxygenated blood at low pressure from the pulmonary artery\n4. Collateral vessels develop between the right coronary artery (from aorta) and left coronary artery\n5. Blood flows from the high-pressure right coronary system through collaterals to the left coronary territory\n6. This blood then flows RETROGRADE through the left coronary artery INTO the pulmonary artery (which has lower pressure)\n\nThis creates a \"coronary steal\" phenomenon where blood is shunted away from the myocardium into the pulmonary artery.\n\nThe diagnostic finding on color Doppler in ALCAPA is:\n- Retrograde flow in the left coronary artery going INTO the pulmonary artery\n- This appears as flow going from the left coronary ostium into the main pulmonary artery\n\nLet me evaluate the options:\n- A: Diastolic flow from aorta to LCA - This is normal coronary flow\n- B: Systolic flow from PA to LCA - This would be antegrade flow, but in ALCAPA the flow is actually retrograde (from LCA to PA) due to collateral development\n- C: Retrograde flow from LCA into PA - This is the classic finding in ALCAPA\n- D: Continuous flow from aorta to PA - This describes a PDA or aortopulmonary window\n- E: Turbulent high-velocity flow at LCA ostium - Non-specific\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-007", "question": "A 60-year-old male presents with nephrotic syndrome. Labs show low serum C3 and normal C4. Kidney biopsy reveals C3-dominant staining on immunofluorescence and a membranoproliferative pattern on light microscopy. Serum protein electrophoresis is negative, but serum free light chain assay shows a kappa:lambda ratio of 5.0. What is the most appropriate treatment to preserve renal function?", "options": ["Option A: Eculizumab", "Option B: Mycophenolate Mofetil", "Option C: Clone-directed chemotherapy (e.g., Bortezomib-based)", "Option D: High-dose steroids alone", "Option E: Plasma exchange"], "answer": "C", "answer_index": 2, "explanation": "This patient has C3 Glomerulopathy (C3G) secondary to a Monoclonal Gammopathy of Renal Significance (MGRS). The monoclonal protein acts as an autoantibody (e.g., C3 nephritic factor) driving complement activation. The standard of care is to treat the underlying clone (plasma cell directed therapy) rather than non-specific immunosuppression or complement inhibition alone.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nKey findings:\n- 60-year-old male with nephrotic syndrome\n- Low C3, normal C4 (suggests alternative pathway activation)\n- C3-dominant staining on immunofluorescence\n- Membranoproliferative pattern on light microscopy\n- Negative serum protein electrophoresis (SPEP)\n- Abnormal kappa:lambda ratio of 5.0 (normal is ~0.26-1.65)\n\nDiagnosis:\nThis is C3 glomerulopathy (C3G) with a membranoproliferative pattern. The low C3 with normal C4 indicates alternative complement pathway dysregulation. The C3-dominant staining confirms C3 glomerulopathy.\n\nCritical finding:\nThe abnormal free light chain ratio (5.0) with negative SPEP suggests a monoclonal gammopathy. This is important because:\n- Monoclonal gammopathy can cause C3 glomerulopathy through monoclonal immunoglobulin acting as an autoantibody against complement regulatory proteins (like Factor H) or stabilizing C3 convertase\n- This is called \"Monoclonal gammopathy of renal significance\" (MGRS)-associated C3G\n\nTreatment considerations:\n- Option A (Eculizumab): Terminal complement inhibitor, used in some C3G cases but doesn't address the underlying clone\n- Option B (MMF): Immunosuppression, not first-line for clone-driven disease\n- Option C (Clone-directed chemotherapy): Targets the underlying monoclonal B-cell/plasma cell clone producing the pathogenic immunoglobulin\n- Option D (High-dose steroids): Insufficient for clone-driven disease\n- Option E (Plasma exchange): May temporarily remove the monoclonal protein but doesn't address the source\n\nBest answer:\nWhen C3 glomerulopathy is driven by a monoclonal gammopathy (MGRS), the treatment should target the underlying clone. Clone-directed therapy (such as bortezomib-based regimens for plasma cell clones) addresses the root cause and has shown efficacy in MGRS-associated kidney disease.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-008", "question": "A patient with severe ARDS is ventilated in Assist-Control Volume Control mode. He is deeply sedated but not paralyzed. Ventilator graphics display a time-triggered mandatory breath, followed immediately by a drop in esophageal pressure (diaphragmatic contraction) occurring during the inspiratory phase, which triggers a second breath during exhalation (breath stacking). This phenomenon is best described as:", "options": ["Option A: Double triggering due to flow starvation", "Option B: Reverse triggering", "Option C: Ineffective triggering", "Option D: Premature cycling", "Option E: Auto-triggering"], "answer": "B", "answer_index": 1, "explanation": "Reverse triggering is a form of patient-ventilator dyssynchrony where the passive insufflation from the ventilator mechanically stretches the diaphragm, reflexively inducing a patient respiratory effort (entrainment). If this induced effort is strong enough, it can trigger a second breath (breath stacking). It is distinct from double triggering caused by high patient drive.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this step by step.\n\nThe key features in this scenario:\n1. Patient has severe ARDS on AC-VC mode\n2. Deeply sedated but NOT paralyzed\n3. A time-triggered mandatory breath occurs FIRST\n4. THEN a drop in esophageal pressure (diaphragmatic contraction) occurs during the inspiratory phase\n5. This triggers a second breath during exhalation (breath stacking)\n\nThe sequence is critical here: the ventilator breath comes FIRST, and THEN the patient's diaphragmatic effort follows.\n\nLet me consider each option:\n\nA. Double triggering due to flow starvation - This occurs when patient effort triggers two breaths, typically because the set inspiratory time is shorter than the patient's neural inspiratory time. The patient initiates the breath.\n\nB. Reverse triggering - This is when a ventilator-delivered breath triggers/entrains diaphragmatic activity. The mechanical breath comes first, and the patient's respiratory effort is triggered BY the ventilator breath. This matches our scenario perfectly - time-triggered breath first, then diaphragmatic contraction follows.\n\nC. Ineffective triggering - This is when patient effort fails to trigger a breath, not when extra breaths occur.\n\nD. Premature cycling - This is when the ventilator cycles to exhalation before the patient's inspiratory effort is complete, but doesn't specifically describe the phenomenon of ventilator-induced diaphragmatic activity.\n\nE. Auto-triggering - This occurs when the ventilator is triggered by something other than patient effort (like cardiac oscillations, circuit leaks), not by diaphragmatic contraction.\n\nThe key distinguishing feature is that the TIME-TRIGGERED (not patient-triggered) breath occurs FIRST, and then the diaphragmatic contraction follows. This is the hallmark of reverse triggering - where the mechanical breath entrains/triggers the patient's respiratory drive, rather than the other way around. This phenomenon is particularly seen in deeply sedated patients.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-009", "question": "A 28-year-old G2P2 woman presents 3 months postpartum with extensive ecchymoses and bleeding from a minor cut. Coagulation studies show aPTT 78s and PT 12s. A mixing study fails to correct the aPTT. Factor VIII activity is <1%. Which agent is the most appropriate first-line therapy for acute bleeding control?", "options": ["Option A: Desmopressin (DDAVP)", "Option B: Cryoprecipitate", "Option C: Recombinant Human Factor VIII", "Option D: Recombinant Porcine Factor VIII", "Option E: High-dose Prednisone"], "answer": "D", "answer_index": 3, "explanation": "This is acquired hemophilia A (postpartum), caused by an inhibitor (autoantibody) to Factor VIII. Human Factor VIII (and Cryoprecipitate) will be neutralized by the inhibitor and is ineffective. First-line hemostatic agents are bypassing agents (rFVIIa or FEIBA) or Recombinant Porcine Factor VIII (which has low cross-reactivity with human anti-FVIII antibodies). Prednisone treats the clone but does not stop acute bleeding.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Let me analyze this case step by step.\n\nClinical Presentation:\n- 28-year-old woman, 3 months postpartum\n- Extensive ecchymoses and bleeding from minor cut\n- aPTT: 78s (prolonged)\n- PT: 12s (normal)\n- Mixing study: fails to correct aPTT\n- Factor VIII activity: <1%\n\nKey Diagnostic Points:\n1. Isolated prolonged aPTT with normal PT suggests intrinsic pathway problem\n2. Mixing study fails to correct - this is crucial! This indicates the presence of an inhibitor (antibody) rather than a factor deficiency\n3. Very low Factor VIII (<1%) in a postpartum woman with an inhibitor = Acquired Hemophilia A\n\nAcquired Hemophilia A is characterized by autoantibodies against Factor VIII, often occurring postpartum.\n\nTreatment Considerations:\n\n- Option A (DDAVP): Works by releasing endogenous Factor VIII stores. Not effective when there's an inhibitor that will neutralize the released Factor VIII.\n\n- Option B (Cryoprecipitate): Contains Factor VIII, but the inhibitor will neutralize human Factor VIII.\n\n- Option C (Recombinant Human Factor VIII): The inhibitor (anti-Factor VIII antibody) will neutralize human Factor VIII, making this ineffective.\n\n- Option D (Recombinant Porcine Factor VIII): Porcine Factor VIII has different epitopes than human Factor VIII. The autoantibodies in acquired hemophilia A typically have lower cross-reactivity with porcine Factor VIII, making it effective for acute bleeding control. Susoctocog alfa (recombinant porcine Factor VIII) is specifically approved for acquired hemophilia A.\n\n- Option E (High-dose Prednisone): This is used for immunosuppression to eliminate the inhibitor long-term, but it won't provide immediate bleeding control.\n\nFirst-line therapy for acute bleeding in acquired hemophilia A:\n- Bypassing agents (rFVIIa, aPCC) or recombinant porcine Factor VIII are the treatments of choice for acute bleeding control.\n\nGiven the options provided, recombinant porcine Factor VIII is the most appropriate first-line therapy for acute bleeding control in this patient with acquired hemophilia A.\n\nThe answer is (D)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-010", "question": "A traveler returns from Malaysian Borneo with daily high-grade fevers and severe thrombocytopenia. Blood smear reveals high parasitemia with 'band form' trophozoites resembling Plasmodium malariae, but the clinical severity mimics Plasmodium falciparum. Which feature distinguishes the replication cycle of this pathogen from P. falciparum?", "options": ["Option A: 24-hour erythrocytic cycle", "Option B: 48-hour erythrocytic cycle", "Option C: 72-hour erythrocytic cycle", "Option D: Presence of a hypnozoite stage", "Option E: Preferential invasion of reticulocytes"], "answer": "A", "answer_index": 0, "explanation": "The pathogen is Plasmodium knowlesi, a zoonotic malaria. A key feature driving its potential for hyperparasitemia and severe disease is its unique 24-hour (quotidian) erythrocytic replication cycle. P. falciparum has a 48-hour cycle, and P. malariae has a 72-hour cycle. P. knowlesi does not have a hypnozoite stage (unlike P. vivax/ovale).", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nThe clinical scenario describes:\n- Travel to Malaysian Borneo\n- High-grade daily fevers\n- Severe thrombocytopenia\n- High parasitemia\n- \"Band form\" trophozoites resembling P. malariae\n- Clinical severity mimicking P. falciparum\n\nThis presentation is classic for Plasmodium knowlesi, a zoonotic malaria parasite transmitted from macaques to humans, particularly in Southeast Asia (Malaysian Borneo is a hotspot).\n\nKey features of P. knowlesi:\n- Band-form trophozoites that look like P. malariae on microscopy\n- Can cause severe disease similar to P. falciparum\n- Has a 24-hour erythrocytic cycle (quotidian fever pattern - daily fevers)\n- Can achieve high parasitemia rapidly due to the short replication cycle\n\nNow comparing to P. falciparum:\n- P. falciparum has a 48-hour erythrocytic cycle\n- P. falciparum does NOT have hypnozoites\n- P. falciparum invades RBCs of all ages (not preferentially reticulocytes)\n\nThe distinguishing feature of P. knowlesi from P. falciparum:\n\n- Option A (24-hour cycle): P. knowlesi has a 24-hour cycle; P. falciparum has 48-hour - this IS different\n- Option B (48-hour cycle): Both would be similar if this were the case - not distinguishing\n- Option C (72-hour cycle): This is P. malariae's cycle\n- Option D (Hypnozoites): Neither P. knowlesi nor P. falciparum have hypnozoites\n- Option E (Reticulocyte preference): P. knowlesi can invade all RBC ages like P. falciparum\n\nThe key distinguishing feature is the 24-hour erythrocytic cycle of P. knowlesi, which explains the daily (quotidian) fevers and rapid progression to high parasitemia and severe disease.\n\nThe answer is (A)"}]